Magnum's Valuation and Market Position: Unilever's gelato business, including Magnum Ice Cream, is set to be listed on the Amsterdam stock exchange with a valuation of around $16 billion, reflecting slow growth and a narrow focus compared to competitors like Mondelez International.
Challenges Facing the Business: The ice cream segment has seen less than 3% annual sales growth over the past two years, lagging behind Unilever's beauty and wellness division, while high supply chain costs and public disputes with Ben & Jerry's founders may impact valuation.
Cost-Cutting and Growth Strategies: CEO Peter ter Kulve plans to implement €500 million in cost cuts and aims to diversify the product line by marketing lower-calorie options and expanding successful brands like Yasso beyond the U.S.
Potential for Increased Valuation: If Magnum can achieve a faster growth rate and improved profitability, it could be valued at nearly €19 billion, but this will depend on adapting to changing consumer preferences and the impact of weight-loss drugs on demand.
Wall Street analysts forecast MDLZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLZ is 66.82 USD with a low forecast of 62.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast MDLZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLZ is 66.82 USD with a low forecast of 62.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
5 Hold
0 Sell
Moderate Buy
Current: 57.580
Low
62.00
Averages
66.82
High
84.00
Current: 57.580
Low
62.00
Averages
66.82
High
84.00
JPMorgan
Overweight
downgrade
$71 -> $69
2026-01-21
New
Reason
JPMorgan
Price Target
$71 -> $69
AI Analysis
2026-01-21
New
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Mondelez to $69 from $71 and keeps an Overweight rating on the shares ahead of the Q4 report on February 3. The firm believes the company's 2026 earnings "inflection" could be back-half weighted given its pressures from stepped up spending and volume challenges to start off the year.
BTIG
David Larsen
Buy
maintain
$50 -> $55
2026-01-21
New
Reason
BTIG
David Larsen
Price Target
$50 -> $55
2026-01-21
New
maintain
Buy
Reason
BTIG analyst David Larsen raised the firm's price target on Medline to $55 from $50 and keeps a Buy rating on the shares following the JP Morgan Healthcare Conference. The company provided a high-level overview for those who were new to the business, including highlights of its two key segments Medline Brand and Supply Chain Solutions, the analyst tells investors in a research note. BTIG is positive on the way Medline serves the entire healthcare continuum, and its Prime Vendor relationships are sticky, with a 98% retention rate.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDLZ
Unlock Now
TD Cowen
Robert Moskow
Buy
downgrade
$68 -> $62
2026-01-08
Reason
TD Cowen
Robert Moskow
Price Target
$68 -> $62
2026-01-08
downgrade
Buy
Reason
TD Cowen analyst Robert Moskow lowered the firm's price target on Mondelez to $62 from $68 and keeps a Buy rating on the shares. The firm adjusted price targets in consumer staples as part of a 2026 outlook. TD expects a "challenging" year for large-cap consumer staples with volume growth unlikely to improve materially from the negative 0.9% in 2025 and pricing "muted."
Mizuho
Outperform
to
NULL
downgrade
$70 -> $67
2026-01-08
Reason
Mizuho
Price Target
$70 -> $67
2026-01-08
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on Mondelez to $67 from $70 and keeps an Outperform rating on the shares. The firm adjusted targets in the food producers space as part of its 2026 outlook. Healthy living growth should outperform in 2026, but concerns for competition have compressed valuations, the analyst tells investors in a research note. Mizuho believes weak fundamentals and elevated macro uncertainty "suggest limited prospects for a broad valuation recovery."
About MDLZ
Mondelez International, Inc. is a snack company. The Company’s core business is making and selling chocolate, biscuits and baked snacks. The Company also has additional businesses in adjacent, locally relevant categories including gum and candy, cheese and grocery and powdered beverages. Its portfolio includes global and local brands such as Oreo, Ritz, LU, Clif Bar and Tate’s Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka and Toblerone chocolate. The Company’s segments include Latin America, AMEA, Europe and North America. It sells its products in over 150 countries and has operations in approximately 80 countries, including 147 principal manufacturing and processing facilities across 46 countries. It sells its products to supermarket chains, wholesalers, supercenters, club stores, mass merchandisers, distributors, convenience stores, gasoline stations, drug stores, value stores and other retail food outlets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
